RU2016126423A - Композиции и способы лечения внутримозгового кровоизлияния - Google Patents

Композиции и способы лечения внутримозгового кровоизлияния Download PDF

Info

Publication number
RU2016126423A
RU2016126423A RU2016126423A RU2016126423A RU2016126423A RU 2016126423 A RU2016126423 A RU 2016126423A RU 2016126423 A RU2016126423 A RU 2016126423A RU 2016126423 A RU2016126423 A RU 2016126423A RU 2016126423 A RU2016126423 A RU 2016126423A
Authority
RU
Russia
Prior art keywords
less
ich
mmhg
leu
seq
Prior art date
Application number
RU2016126423A
Other languages
English (en)
Russian (ru)
Other versions
RU2016126423A3 (enExample
Inventor
Стивен АРКИН
Хоаким ФРУБИС
Маркус И. КАРР
Санита ХЕТТ
Реема ДЖАСУДЖА
Дебра Д. ПИТТМАН
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of RU2016126423A publication Critical patent/RU2016126423A/ru
Publication of RU2016126423A3 publication Critical patent/RU2016126423A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2016126423A 2014-01-24 2015-01-15 Композиции и способы лечения внутримозгового кровоизлияния RU2016126423A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
US61/931,071 2014-01-24
PCT/IB2015/050313 WO2015110939A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Publications (2)

Publication Number Publication Date
RU2016126423A true RU2016126423A (ru) 2018-03-01
RU2016126423A3 RU2016126423A3 (enExample) 2018-03-01

Family

ID=52630418

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016126423A RU2016126423A (ru) 2014-01-24 2015-01-15 Композиции и способы лечения внутримозгового кровоизлияния

Country Status (18)

Country Link
US (2) US20160375109A1 (enExample)
EP (1) EP3096779B1 (enExample)
JP (1) JP6624787B2 (enExample)
KR (3) KR20180014221A (enExample)
CN (2) CN112156176A (enExample)
AU (1) AU2015208819B2 (enExample)
BR (1) BR112016014617A2 (enExample)
CA (1) CA2937418A1 (enExample)
DK (1) DK3096779T3 (enExample)
ES (1) ES2772802T3 (enExample)
HU (1) HUE047588T4 (enExample)
IL (1) IL246637A0 (enExample)
MX (1) MX375355B (enExample)
PL (1) PL3096779T3 (enExample)
PT (1) PT3096779T (enExample)
RU (1) RU2016126423A (enExample)
SI (1) SI3096779T1 (enExample)
WO (1) WO2015110939A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2761730T3 (es) * 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP3049434A1 (en) 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005123118A1 (en) * 2004-06-21 2005-12-29 Novo Nordisk Health Care Ag Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
MX2008006313A (es) 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
JP2011509978A (ja) * 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
ES2605801T3 (es) * 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US9371522B2 (en) * 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
WO2014018120A1 (en) * 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
ES2761730T3 (es) * 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa

Also Published As

Publication number Publication date
EP3096779B1 (en) 2019-12-18
US20190231856A1 (en) 2019-08-01
AU2015208819B2 (en) 2020-01-23
ES2772802T3 (es) 2020-07-08
MX2016009665A (es) 2016-11-14
CA2937418A1 (en) 2015-07-30
JP2015147764A (ja) 2015-08-20
HUE047588T4 (hu) 2020-06-29
EP3096779A1 (en) 2016-11-30
US20160375109A1 (en) 2016-12-29
IL246637A0 (en) 2016-08-31
DK3096779T3 (da) 2020-02-24
AU2015208819A1 (en) 2016-06-30
WO2015110939A1 (en) 2015-07-30
KR20160093731A (ko) 2016-08-08
MX375355B (es) 2025-03-04
CN112156176A (zh) 2021-01-01
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
BR112016014617A2 (pt) 2017-09-19
SI3096779T1 (sl) 2020-03-31
KR20180014221A (ko) 2018-02-07
RU2016126423A3 (enExample) 2018-03-01
JP6624787B2 (ja) 2019-12-25
HUE047588T2 (hu) 2020-04-28
CN105934250A (zh) 2016-09-07
PT3096779T (pt) 2020-02-21

Similar Documents

Publication Publication Date Title
US10688154B2 (en) Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
Cerri et al. Chemokines as new inflammatory players in the pathogenesis of epilepsy
RU2010140886A (ru) Применение дефенсинов при туберкулезе
RU2707191C2 (ru) Нейродегенеративные расстройства
Wang et al. Glimepiride and glibenclamide have comparable efficacy in treating acute ischemic stroke in mice
EP3463575B1 (en) Methods and compositions for modulating lymphatic vessels in the central nervous system
CN101288768A (zh) 用于治疗渐进神经退化症的医药组合物
KR20150018555A (ko) 뇌졸중 후 신경발생을 촉진시키는 세마포린-４d 결합 분자의 용도
RU2016126423A (ru) Композиции и способы лечения внутримозгового кровоизлияния
JP2020502140A (ja) 糖尿病を治療するための新しい方法
Faraji et al. Harnessing BDNF signaling to promote resilience in aging
Tang et al. TREM2 alleviates long-term cognitive dysfunction after subarachnoid hemorrhage in mice by attenuating hippocampal neuroinflammation via PI3K/Akt signaling pathway
KR102657418B1 (ko) 신경 보호 및 신경 질환에서의 cgrp 수용체 길항제의 용도
Shi et al. EA participates in pain transition through regulating KCC2 expression by BDNF-TrkB in the spinal cord dorsal horn of male rats
WO2017180841A1 (en) Treatment of cerebral cavernous malformations
JP2015147764A5 (enExample)
Wei et al. Increased CD147 (EMMPRIN) expression in the rat brain following traumatic brain injury
US20130165376A1 (en) Heparin Binding Epidermal Growth Factor (HB-EGF) for Use in Methods of Treating and Preventing Intestinal Injury Related to Hemorrhagic Shock and Resuscitation
US20190002517A1 (en) Neuropeptide y-derived peptides
Gu et al. Expression and regulation of versican in neural precursor cells and their lineages
MX2021003123A (es) Isomeros rotomericos de 4-alquil-5-heteroaril-3h-1,2-ditiol-3-tion as.
WO2015121428A1 (en) Polypeptide fragments of 168a-t2 and compositions comprising them for use in treating cancer
Liu et al. Effect of hydrogen-rich water on the angiogenesis in lesion boundary brain tissue of traumatic brain injury-challenged rats
WO2015136255A1 (en) Combined inhibition of caspase-2 and caspase-6 in neuroprotection and axon regeneration
Maghsoudi et al. Intraperitoneal Carbamylated erythropoietin improves memory and hippocampal apoptosis in beta-amyloid rat model of Alzheimer’s disease through stimulating autophagy and inhibiting necroptosis

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190121